'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset Read more 

AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor Read more 

Epicrispr gene silencer is 1st drug to boost muscle in form of muscular dystrophy, biotech says Read more 

About Charles Muriuki

This author has not yet filled in any details.
So far Charles Muriuki has created 2 blog entries.
Go to Top